FDA approves biosimilar STIMUFEND® (pegfilgrastim)

Fresenius Kabi announced on September 6 that the United States (U.S.) Food and Drug Administration (FDA) has approved its pegfilgrastim biosimilar, Stimufend®, for use in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.